Steadily advancing up the value chain
from intermediates to advanced APIs, biologics, and next-generation platforms, including enzyme, metabolite, and small-molecule engineering and cell-free systems.
Deep expertise in fermentation science,
spanning strain development, process intensification, and the commercial-scale manufacturing of complex molecules.
A pipeline of 10–12 new products in development,
positioned to support growth from FY27 onwards.
An expanding biologics capability spanning recombinant technologies, peptides, and therapeutic proteins.
A firm commitment to green chemistry principles across every process we operate.
Strengthened by the scientific and commercial capabilities of the wider Themis ecosystem.
An established development-to-manufacturing partner for critical and emerging therapies.
